Gent

• A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Ended recruitment
  2023-505625-14-00 7 2017-01-31 Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
• Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended recruitment
  2023-505699-31-00 5 2017-01-02 Ulcerative Colitis
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth … Ended recruitment
  2022-501017-31-00 5 2016-05-10 Rheumatoid arthritis
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res … Ended recruitment
  2023-509221-47-00 5 2014-02-12 Castration-Resistant Prostate Cancer
• An Extension Study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients pr … Ended recruitment
  2023-503479-79-00 4 2011-06-17 Metastatic Cancer
• CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer Halted
  2024-517190-24-00 4 2025-09-16 Peritoneal Cancer
• A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants w … Halted
  2024-516095-15-00 1 2025-08-05 Kidney Disease
• Public title :A Phase 1b/2a trial to evaluate Invobenitug also known as Procizumab (PCZ; AK1967) in critical cardiovascular care. Halted
  2024-518450-16-00 9 2025-06-13 Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) Halted
  2023-507820-22-00 3 2024-05-22 Progressive Multiple Sclerosis (PMS)
• Dosimetry of a novel amino acid PET tracer, [18F]FELP Halted
  2022-501696-91-00 1 2024-04-10 Glioblastoma
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator … Halted
  2024-512626-28-00 5 2024-03-28 Duchenne Muscular Dystrophy
• Posaconazole (MK-5592) IV and oral in children (less than 2 years) with IFI Halted
  2023-505613-24-00 4 2021-04-28 Fungal infection
• A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002) Ended
  2025-524852-74-00 3 2026-03-11 Hypercholesterolaemia
• A study to assess the immune response and safety of a vaccine against influenza in adults 18 years of age and older Ended
  2025-522599-97-00 4 2025-10-30 Influenza, Human
• A clinical study of MK-4082 in healthy people (MK-4082-001) Ended
  2025-522100-25-00 1 2025-10-09 Weight management
• A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the bo … Ended
  2023-507905-33-00 1 2025-09-30 Advanced solid tumors
• Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of … Ended
  2024-520354-37-00 4 2025-09-08 Influenza disease
• Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis Ended
  2024-517623-39-00 5 2025-08-25 inclusion body myositis
• A randomized active-controlled trial for vulvovaGinal atRophy in breAst Cancer patients on Endocrine therapy (GRACE-trial) Ended
  2024-510845-33-00 6 2025-06-23 Breast cancer patients on endocrine therapy (AI or SERM) with symptoms
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)

Showing 697–720 of 922 trials